Table 1 Characteristics of the study cohort, overall and by fracture outcome
From: Measuring improvement in fracture risk prediction for a new risk factor: a simulation
Overall (N = 31,999) | No MOF (N = 28,817) | MOF (N = 3182) | |
|---|---|---|---|
Age (years) | 65.6 ± 9.7 | 65.1 ± 9.6 | 70.2 ± 9.7 |
Body mass index (kg/m2) | 26.7 ± 5.2 | 26.8 ± 5.2 | 25.7 ± 4.9 |
Prior fracture, n (%) | 3977 (12.4) | 3228 (11.2) | 749 (23.5) |
Parental hip fracture, n (%) | 520 (1.6) | 492 (1.7) | 28 (0.9) |
COPD, n (%) | 3084 (9.6) | 2648 (9.2) | 436 (13.7) |
Recent glucocorticoid use, n (%) | 1502 (4.7) | 1267 (4.4) | 235 (7.4) |
Rheumatoid arthritis, n (%) | 1277 (4.0) | 1065 (3.7) | 212 (6.7) |
Alcohol or substance abuse, n (%) | 614 (1.9) | 517 (1.8) | 97 (3.0) |
Femoral neck T-score | − 1.5 ± 1.0 | − 1.4 ± 1.0 | − 2.1 ± 0.9 |
FRAX® MOF risk | 11.1 ± 7.4 | 10.5 ± 6.8 | 16.3 ± 9.6 |
Follow up (years) | 8.4 ± 2.8 | 8.4 ± 2.8 | 8.9 ± 2.8 |